# EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

> **NCT02942160** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 259 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy
- Cellulite

## Interventions

- **BIOLOGICAL:** Collagenase Clostridium Histolyticum

## Key facts

- **NCT ID:** NCT02942160
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-05
- **Primary completion:** 2018-06-14
- **Final completion:** 2018-06-14
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942160, "EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02942160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*